2133. Surveillance of Eravacycline Against Gram-positive Clinical Pathogens, Including Resistant Isolates, Collected Worldwide From Multiple Infection Sites During 2021

BACKGROUND: Eravacycline is a fully synthetic, fluorocycline approved for the treatment of complicated intra-abdominal infections (cIAI) in patients ≥18 years of age in Europe, Singapore, Hong Kong, mainland China, the US, and the UK. Previous surveillance studies of eravacycline have demonstrated p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawser, Stephen, Kothari, Nimmi, Monti, Federica, Hodges, Tony, Zappas, Kristie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677593/
http://dx.doi.org/10.1093/ofid/ofad500.1756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677593/
http://dx.doi.org/10.1093/ofid/ofad500.1756

Ejemplares similares